Cytokine storm during chemotherapy: A new companion diagnostic emerges? by Filippou, Panagiota S. & Karagiannis, George S.
Oncotarget213www.oncotarget.com
www.oncotarget.com                                                     Oncotarget, 2020, Vol. 11, (No. 3), pp: 213-215
Cytokine storm during chemotherapy: a new companion diagnostic 
emerges?
Panagiota S. Filippou and George S. Karagiannis
Despite that chemotherapy represents the frontier 
cancer treatment today, aggregating evidence in pre-
clinical animal models and small patient cohorts 
paradoxically suggests that certain cancers often elicit pro-
tumorigenic and pro-metastatic phenotypes in response to 
standard chemotherapy regimens. This phenotype is now 
believed to occur through a cancer-mediated secretion 
of pro-inflammatory cytokines, chemokines and other 
mediators, collectively known as the “cytokine storm”, 
initially affecting the local tumor microenvironment, but 
subsequently released in peripheral circulation, where it 
elicits systemic tumor-promoting effects [1]. Two recent, 
seminal studies in this context, the first by Karagiannis 
et al. (2017) in Science Translational Medicine [2], and 
the second by Gartung et al. (2019) in Proceedings of the 
National Academy of Sciences (PNAS) [3], have shed 
useful insights on the molecular mechanisms underlying 
the pro-tumoral shift of the tumor microenvironment 
upon treatment with chemotherapy. When appreciated 
individually, each study reveals a unique piece of the 
puzzle, but valued together, they offer an attractive model 
on how “chemotherapy-induced metastasis” is regulated at 
the microanatomical level.
Generally, tumor-associated macrophages (TAMs) 
represent a proponent compartment of the tumor 
microenvironment and they are well-documented to 
promote tumor angiogenesis, metastasis, and local 
immunosuppression, as well as to obscure tumor 
response to various cancer treatment modalities, 
including chemotherapy, immunotherapy and targeted 
antiangiogenic therapy [1]. Of note, a specialized TAM 
subpopulation exerting M2 (or M2-like) polarization 
status that expresses the tyrosine kinase receptor 
Tie2 (Tie2+ TAMs) has been recently identified as the 
master regulator of tumor angiogenesis and cancer cell 
intravasation and dissemination. Interestingly, Tie2+ 
macrophages do not only regulate cancer angiogenesis, but 
they have been notorious for assembling tripartite micro-
anatomical doorways called Tumor Microenvironment 
of Metastasis (TMEM), which are composed of one 
tumor cell overexpressing the actin-regulatory protein 
Mammalian enabled (Mena), one pro-angiogenic Tie2+ 
macrophage, and one underlying endothelial cell, all 
three in direct physical juxtaposition to one another. 
Such TMEM doorways function as active sites of cancer 
cell dissemination, and they can literally gunfire highly-
migratory, highly-invasive tumor cells into the peripheral 
circulation. TMEM activity is conveniently regulated by 
the Tie2+ TAM through the local secretion of vascular 
endothelial growth factor-A (VEGF-A), and as such, 
tumors with high TMEM density and activity have an 
increased risk for developing metastatic disease [1]. In the 
seminal study by Karagiannis et al. (2017), it was shown 
that preoperative (i.e., neo-adjuvant) chemotherapy with 
taxane (i.e., paclitaxel) or non-taxane (i.e., doxorubicin/ 
cyclophosphamide) chemotherapeutics induced the 
recruitment of Tie2+ macrophages in the primary breast 
tumor microenvironment, subsequently promoting TMEM 
doorway assembly and function, leading to a prominent 
increase of circulating tumor cells and metastatic 
dissemination and disease [2]. Similar (or relevant) 
observations have been described by other research 
groups ever since [for detailed description on those studies 
refer to Sanchez et al. (2019) [1], and the references 
within], collectively suggesting that chemotherapy-
driven metastasis is mediated by influx of pro-metastatic 
myeloid cells (specifically macrophages) and endothelial 
progenitors.
Nevertheless, an unresolved, yet critical, question 
rising from Karagiannis et al. (2017) at the time was related 
to the precise mechanism via which Tie2+ macrophages 
were seen to be recruited in primary breast tumors upon 
treatment with neoadjuvant chemotherapy. Prior literature 
[1], along with the key observation that identical TMEM-
mediated pro-metastatic responses were not dependent on 
the category of the chemotherapeutic used [2], prompted 
the idea that Tie2+ TAM influx is the cumulative result 
of a host repair-mechanism against cancer cell apoptosis, 
hypoxia and extensive tissue damage, as elicited by the 
cytotoxic nature of chemotherapy. This speculation has been 
confirmed in the elegant study by Gartung et al. (2019), 
which profiled the pro-inflammatory mediators released 
upon treatment with neo-adjuvant chemotherapy in ovarian 
cancer [3]. Strikingly, ovarian cancer cell debris resulting 
from cytotoxic tissue damage was capable per se to elicit 
therapy-induced tumor progression, by enforcing the 
release of the cytokine storm systemically [3]. This study 
highlighted that circulating levels of tumor necrosis factor-
alpha (TNF-α), C-C motif chemokine ligand-2 (CCL2), 
and interleukin 6 (IL-6) were significantly increased upon 
chemotherapy, and suggested that these cytokines could 
drive chemotaxis of other cytokine-releasing stromal/
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immune cells, thus perpetuating a pro-inflammatory vicious 
cycle supporting hallmarks of tumor growth and progression 
[3]. Certain cytokines, such as the ones mentioned above, 
have been demonstrated to be involved in monocyte/
macrophage chemotaxis, infiltration, maturation, and their 
functional implications within the tumor microenvironment 
[1], and more importantly, Gartung et al. (2019) identified 
and validated these key cytokines using unbiased high-
throughput analyses [3].
In general, cytokines are molecules with key 
roles in intercellular communication within the tumor 
microenvironment, and certain of them have already been 
proposed as therapeutic cancer targets [4]. Interestingly, 
cancer cells and the tumor microenvironment can 
create a surge in cytokine production, termed “cytokine 
storm”, upon treatment with chemotherapy [1, 3, 4], as 
described above. These cytokines are not only responsible 
for generating a tumor- and metastasis-promoting 
microenvironment in cancer, including the establishment 
of the pre-metastatic niche, but may also be involved in 
drug resistance and chemoresistance. Cytokines modulate 
the release of growth factors, or even other cytokines, 
thus perpetuating a pro-inflammatory, pro-invasive and 
pro-metastatic loop within the tumor microenvironment. 
Cancer cells readily respond to such host-derived cytokines 
to acquire designated hallmarks of cancer, including 
survival, apoptosis evasion, invasion and metastasis [4]. 
Because of such debilitating and promiscuous functions, 
cytokine identification and quantification in both the 
local or distant tumor microenvironment and in the blood 
circulation have been at the frontier of translational 
research, which examines their potential application as 
diagnostic, prognostic, or predictive biomarkers. Indeed, 
technological advancements and innovative, state-of-
the art analytical approaches have granted us the ability 
to study and measure this complex cytokine network at 
the systemic level. A wide range of cytokine assays is 
available nowadays: i) direct measurement of cytokines 
or indirect measurement of cytokine soluble receptors 
in body fluids or cellular supernatants (immunoassays, 
cytokine bioassays, western blot, mass spectrometry); 
ii) cytokine measurement produced by cell populations 
(multiparametric flow cytometry, magnetic bead-based 
quantitation of cytokine producing cells, mRNA-based 
assays); iii) single cytokine-producing cell analysis 
(ELISpot, flow cytometry, mass cytometry, emerging 
techniques for single cell secretomics and droplet-based 
microfluidic approaches); and finally, iv) cytokine imaging 
at the cellular and tissue levels (immunohistochemistry, 
immunofluorescence, intra-cytoplasmic cytokine staining 
(ICC)) [5].
Given the abundance of the techniques described 
above, the measurement of individual cytokines should, 
in theory, be easily measured in tissues and biological 
fluids. Despite the aforementioned advances however, 
the accurate and reproducible cytokine measurement still 
faces considerable challenges, which typically include 
their context-dependent expression and release, their 
often low concentrations (picomolar levels or lower) in 
biological fluids, and their binding and/or interference 
with other proteins in many common analytical assays 
[5]. One would therefore advocate for the development 
of novel, or the improvement of current, analytical 
techniques that simultaneously measure multiple 
cytokines (e.g., components of the cytokine storm) in the 
form of “cytokine panels”, which are more informative 
and reflective of the true biology and pathology of the 
disease. With the ever-increasing understanding of the 
complex circuitries and interactions within the tumor 
microenvironment, such multiplexing appears to be an 
analytical strategy that will dominate in the future. A 
new era in proteomics and other bioanalytical techniques 
brings this new vision forward with innovative and/or 
ultrasensitive techniques [i.e., multiplex immunoassay 
platforms; mass-spectrometry (MRM-MS); chemi-
luminescent, bead-based (Luminex) and planar antibody 
arrays; Singulex; Simoa; immuno-PCR; proximity 
ligation/extension assay and immunomagnetic reduction 
assay] [5].
Knowing the devastating effects of the cytokine 
storm released upon chemotherapy, as previously 
described [1–3] such powerful tools could be developed 
in the future to assist clinicians in monitoring 
prometastatic responses in patients in the course of 
treatment with neo-adjuvant chemotherapy. Indeed, 
Karagiannis et al. (2017) suggested that breast cancer 
patients receiving neo-adjuvant chemotherapy and not 
achieving pathologic, complete or partial, response 
(pCR) attract significantly more Tie2+ macrophages 
assembling TMEM doorways, thus putting this patient 
subpopulation in a high-risk group of developing distant 
metastasis later in their lifetime [2]. In a complementary 
fashion, Gartung et al. (2019) has identified and 
quantified certain components of the chemotherapy-
elicited cytokine storm that function as perpetrators 
of this phenotype [3]. Unfortunately, these studies [2, 
3] also underscore our inability, as of the moment, to 
predict which patients will respond with pCR upon 
treatment with neo-adjuvant chemotherapy, thus making 
the analytical strategies described here as perhaps 
the most promising tools for guiding future clinical 
decisions in patient management and care. We therefore 
anticipate that multiplex cytokine signatures will be 
used as companion diagnostics for current therapeutic 
modalities, thus allowing for more “precision” in the era 
of personalized medicine.
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